Tsangaris George Th, Anagnostopoulos Athanasios K
Proteomics Research Unit, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
Data Brief. 2017 Oct 17;15:638-641. doi: 10.1016/j.dib.2017.10.001. eCollection 2017 Dec.
Proteomics, through application of modern high-end mass spectrometric (MS) approaches, offers the advantage of in-depth analysis of cancer tissues regarding their protein composition. Pediatric brain tumor malignancies are scarcely approached by modern holistic technologies (e.g. genomics, proteomics) due to rarity of samples and most importantly difficulty in their collection. Ependymoma, is the third most common tumor in children and is thought to arise from ependymal cells in the wall of the cerebral ventricles or the spinal canal. Due to the heterogeneity of the disease its biological characteristics remain largely unknown and prognostic factors are basically based on clinical and histological criteria. Through application of a modified nanoLC-MS/MS analysis experimental approach we achieved, for the first time, the in-depth examination of the pediatric ependymoma tissue proteome. In the present article we report on the construction of a high-confidence database; the Pediatric Ependymoma Protein Database (PEPD), including 4,157 protein groups originating from the identification and analysis of more than 15,000 peptides. The PEPD offers a first step towards targeted protein validation of the protein content of this specific devastating disease affecting the young population.
蛋白质组学通过应用现代高端质谱（MS）方法，具有深入分析癌症组织蛋白质组成的优势。由于样本稀少，最重要的是收集困难，现代整体技术（如基因组学、蛋白质组学）很少用于小儿脑肿瘤恶性肿瘤的研究。室管膜瘤是儿童中第三常见的肿瘤，被认为起源于脑室壁或椎管内的室管膜细胞。由于该疾病的异质性，其生物学特性在很大程度上仍然未知，预后因素基本上基于临床和组织学标准。通过应用改良的纳升液相色谱-串联质谱（nanoLC-MS/MS）分析实验方法，我们首次实现了对小儿室管膜瘤组织蛋白质组的深入研究。在本文中，我们报告了一个高可信度数据库——小儿室管膜瘤蛋白质数据库（PEPD）的构建，该数据库包含4157个蛋白质组，这些蛋白质组来自对15000多个肽段的鉴定和分析。PEPD为针对这种影响年轻人群的特定毁灭性疾病的蛋白质含量进行靶向蛋白质验证迈出了第一步。
